



Home Generated Sharps Disposal Plan

July 1, 2011

Background:

The State of Minnesota recently enacted a law (**S.F. No. 1323, 3rd Engrossment - 86th Legislative Session (2009-2010)**) requiring any pharmaceutical manufacturer that sells or distributes medication that is self-injected at home through the use of hypodermic needles and other similar devices to post to the company website a plan that describes how the manufacturer supports the safe collection and proper disposal of sharps. The plan shall include at a minimum, a description of the actions, if any, taken by the manufacturer to do the following:

- provide for the safe collection and proper disposal of sharps
- educate consumers about safe management and collection opportunities
- support efforts by retailers, pharmaceutical distributors, local governments, health care organizations, public health officers, solid waste service providers, organizations representing patients who use sharps, and other groups with interest in protecting public health and safety through the sale, collection, and proper disposal of sharps.

This plan is due on July 1, 2011.

GSK Self-Injectable Products Subject To These Regulations

GSK currently markets, distributes, and/or sells two self-injectable products in the State of Minnesota. The brand names of these products are Imitrex® (sumatriptan succinate) Injection and Arixtra® (fondaparinux sodium) Injection.




ARIXTRA® is indicated for the prevention of blood clots after hip fracture, hip or knee replacement surgery or in certain patients after abdominal surgery. This medication is also indicated for the treatment of blood clots. The usual duration of administration of ARIXTRA® is five to nine days.

Imitrex® is indicated for the acute treatment of migraine attacks. There are 2 basic types of migraine-specific therapies — acute and preventative. Acute medications are designed to relieve a migraine after it starts, and preventative medications are designed to help eliminate or significantly reduce the frequency of a person's migraines. Imitrex® Injection is indicated for 1) the acute treatment of migraine attacks with or without aura in adults and 2) the acute treatment of cluster headache episodes in adults. Patients are instructed to administer via injection this medication in accordance with the instruction of a physician or other suitably qualified health care professional.

GSK Supports Safe Collection and Proper Disposal of Home Generated Sharps

GSK has demonstrated a strong commitment to the safe and proper use and disposal of its self-injectable medications. Patient safety and needle stick injury prevention were given serious consideration as the above-mentioned products were being developed. In fact, inherent in the design of both products, GSK used safe needle technology to shield the sharps and provides, at a minimum, approved sharps containers for home generated sharps waste materials.

Specifically, ARIXTRA® uses a 27 gauge needle that is only a half-inch long and the automatic needle protection system retracts the needle once medication is dispensed.

The different parts of ARIXTRA safety syringe are:	
<ol style="list-style-type: none">1. Rigid needle guard2. Plunger3. Finger-grip4. Security sleeve	
 <p>Syringe BEFORE USE</p>	 <p>Syringe AFTER USE</p>

Starter kits, including the Prescribing Information for ARIXTRA®, and an approved sharps container and information leaflet, are offered to Patients via healthcare practitioners.

Additional disposal instructions are provided through the GSK Customer Care Call Center.



Imitrex® Injection is available in the easy-to-use Imitrex® STATdose System, which allows patients to conveniently administer Imitrex with just the push of a button.

The Imitrex® STATdose System includes two small, disposable cartridges pre-filled with a single dose of Imitrex®, and an easy to use autoinjector pen that allows patients to self-administer the medication about one-quarter inch under the skin. With the Imitrex® STATdose System, patients can treat migraines quickly and conveniently while avoiding direct contact with a needle or syringe. After injection, the used sharp is placed into the empty cartridge. Proper disposal instructions are provided through the GSK Customer Care Call Center.



In summary, GlaxoSmithKline supports the safe collection and proper disposal of home generated sharps by providing at no cost to the patient, appropriate sharps disposal containers and educational materials on proper sharps disposal. Patients may contact our Toll Free Customer Call Center Hotline to obtain safe sharps disposal information.